It is also broadening outside of diabetes into related conditions such as cardiovascular disease, fatty liver disease and diabetic kidney disease. Novo’s emphasis on diabetes is unusual among its peers, most of which spread their bets across several disease areas. We had kind of innovated ourselves all the way to the top of the curve, so to speak, in GLP-1 [another diabetes treatment], so that frees up resources. If we find something fantastic for NASH [fatty liver disease] or cardiovascular or kidney disease or obesity, then it’s new patients. MR. THOMSEN: In the heyday of insulin research we had a failure rate of less than 50% from research to market.

Source: Wall Street Journal October 30, 2017 01:52 UTC